Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Schall, Brown & Schwartz LLPSPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawSchall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the...
- DJS Law Group LLPARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRYThe DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by...
- [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesityCompanies: Roche HoldingBasel, 22 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced positive topline results from CT-388-104, a Phase II clinical trial evaluating enicepatide (CT-388), an investigational, once-weekly dual GLP-1/GIP receptor agonist, in adults living with type 2 diabetes (T2D) and overweight or obesity. In the study, enicepatide met both primary endpoints, delivering dose-dependent and clinically meaningful reductions in blood glucose and body weight at 48 weeks. Patients receiving the highest titrated dose (24 mg) achieved an HbA1c reduction of 2.65% (from a baseline HbA1c of 8.1%). Furthermore, 90% of patients in the 24 mg cohort reached an HbA1c level of ≤6.5% (diagnostic threshold for T2D) and 62% achieved normoglycemia (HbA1c < 5.7%), restoring blood glucose levels to a non-diabetic range. The mean weight loss at 48 weeks in the 24 mg enicepatide arm was 15.5% without a demonstrable plateau.
- BestzymeBestzyme Launches World's First Dedicated, Automated Smart Production Line for Sweet Proteins in JinanBestzyme, a synthetic biology company under GenScript Biotech, today announced the completion of the world's first dedicated, automated smart production line for sweet proteins at its Jinan facility. This milestone marks the first full-chain...
- Akeso, Inc.Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that nearly 30 clinical studies of its globally first-in-class bispecific antibodies will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place...
- Merry Life BiomedicalMerry Life Biomedical Advances Global Phase 2 Trial of TML-6, Exploring Cellular Protein Clearance in Early Alzheimer's DiseaseGlobal study brings together nine Taiwan medical centers, seven Swedish sites, and four U.S. centers to evaluate an oral therapy focused on autolysosomal biology — Merry Life Biomedical today announced the advancement of TML-6, a Taiwan-developed...
- The Rosen Law Firm PAROSEN, A TOP-RANKED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
- Robbins Geller Rudman & Dowd LLP1 WEEK CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitRobbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, both dates inclusive (the "Class Period"), have until Monday, September...
- The Rosen Law Firm PAAARD DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages Aardvark Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AARDWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the...
- Helus Pharma NEW YORK andHelus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry SummitCEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT
- Bragar Eagel & Squire, P.C. Urges Capricor Therapeutics, Inc. Investors With Large Losses to Contact the Firm Before the September 28th DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options
- THE ROSEN LAW FIRM, P. A.SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud LawsuitWhy: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead...